America Great Health(OTC) AAGH

America Great Health develops drugs, medical devices, and supplements for healthcare providers and patients. Its products help diagnose diseases, support treatment, and promote wellness. The company’s offerings aim to make healthcare more accessible and efficient.

Products and Services

• Protein and peptide drugs: Develops small molecule drugs, including anti-cancer peptides and oral insulin, for hospitals and clinics. (No segment revenue breakdown disclosed)
• AI diagnostic devices: Sells cloud-based medical devices that use artificial intelligence to help doctors diagnose conditions. (No segment revenue breakdown disclosed)
• Cell therapy and regenerative medicine: Offers products that use living cells to repair or replace damaged tissues, targeting patients with chronic or degenerative diseases. (No segment revenue breakdown disclosed)
• Health supplements: Manufactures and sells nutraceuticals for general wellness, targeting consumers and retail channels. (No segment revenue breakdown disclosed)

Growth and Expansion

• Formed joint venture Sijinsai (Hainan) Biological Tech Ltd. in China for stem cell R&D and sales (2021).
• Acquired 51% equity in Purecell Group (Australia) for anti-aging medicine (pending reversal as of November 2025).
• Launched new products in fiscal year 2025, driving revenue growth.
• Established multiple subsidiaries in the US and China to support expansion and product development since 2017.

What Makes America Great Health Special

The company combines biotechnology with artificial intelligence to create new healthcare solutions. It operates in both the US and China, using partnerships to access technology and markets. Its business model blends drug development, medical devices, and supplements for a diversified approach.

Five Things You Need to Know

• Revenue was $391,743 in FY 2025, up 33.0% from FY 2024.
• Gross profit was $339,121 in FY 2025, up 99.8% from FY 2024.
• Net loss was $(721,242) in FY 2025, improved from $(1,226,362) in FY 2024.
• Three vendors supplied 97% of purchases in FY 2025, showing high supplier concentration.
• Auditor issued a disclaimer of opinion due to insufficient documentation and consolidation issues.

Bottom Line

America Great Health has diversified into drugs, devices, and supplements, expanding through partnerships and new products. The company faces ongoing financial and operational challenges as it seeks stability in a competitive market.